To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

D Shi, D Beasock, A Fessler, J Szebeni… - Advanced drug delivery …, 2022 - Elsevier
Polyethylene glycol or PEG has a long history of use in medicine. Many conventional
formulations utilize PEG as either an active ingredient or an excipient. PEG found its use in …

Clinical relevance of pre-existing and treatment-induced anti-poly (ethylene glycol) antibodies

H Freire Haddad, JA Burke, EA Scott… - Regenerative Engineering …, 2021 - Springer
Abstract Poly (ethylene glycol)(PEG) is a nontoxic, hydrophilic polymer that is often
covalently attached to proteins, drugs, tissues, or materials; a procedure commonly referred …

Complement activation: a potential threat on the safety of poly (ethylene glycol)-coated nanomedicines

A Gabizon, J Szebeni - Acs Nano, 2020 - ACS Publications
In this issue of ACS Nano, Chen et al. provide in vitro and in vivo evidence for monoclonal
anti-poly (ethylene glycol)(anti-PEG) antibody-triggered, complement terminal complex …

Immunogenicity of polyethylene glycol based nanomedicines: mechanisms, clinical implications and systematic approach

N d'Avanzo, C Celia, A Barone, M Carafa… - Advanced …, 2020 - Wiley Online Library
PEGylation technique is currently considered the gold standard approach to provide a long
and safe circulation of drugs. Although this is the accepted dogma, various clinical reports …

Engineering erythrocytes for the modulation of drugs' and contrasting agents' pharmacokinetics and biodistribution

L Rossi, F Pierigè, A Antonelli, N Bigini… - Advanced Drug Delivery …, 2016 - Elsevier
Pharmacokinetics, biodistribution, and biological activity are key parameters that determine
the success or failure of therapeutics. Many developments intended to improve their in vivo …

[HTML][HTML] Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo

G Karpel-Massler, D Ramani, C Shu, ME Halatsch… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Cancer cells display a variety of global metabolic changes, which aside from the glycolytic
pathway largely involve amino acid metabolism. To ensure aggressive growth, tumor cells …

Predicting success of desensitization after pegaspargase allergy

HD Swanson, JC Panetta, PJ Barker… - Blood, The Journal …, 2020 - ashpublications.org
Asparaginase is a critical component of acute lymphoblastic leukemia (ALL) therapy.
Available asparaginase products in the United States include pegaspargase (Oncaspar) …

Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia

P Dharia, MD Swartz, MB Bernhardt, H Chen… - Leukemia & …, 2022 - Taylor & Francis
A total of 548 patients (age range: 1–22 years, 60.4% Hispanic, 55.8% male) diagnosed with
acute lymphoblastic leukemia were reviewed for pegaspargase-associated hypersensitivity …

HLA-DRB1*16:02 is Associated with PEG-Asparaginase Hypersensitivity

S Liu, C Gao, Y Wu, W Lin, J Li, T Xue, L Wang… - …, 2021 - Taylor & Francis
Aim: To evaluate the associations between human leukocyte antigen (HLA)-DRB1 variants
and the rs6021191 variant in nuclear factor of activated T cells 2 (NFATC2) with PEG …

Clinical characteristics of intravenous PEG-asparaginase hypersensitivity reactions in patients undergoing treatment for acute lymphoblastic leukemia

EK Browne, C Moore, A Sykes, Z Lu… - Journal of Pediatric …, 2018 - journals.sagepub.com
Background: Asparaginase poses a substantial risk for hypersensitivity reactions during and
after administration; however, these reactions vary by asparaginase formulation and …